Otros idiomas Exelixis, Inc.

Acciones

EXEL

US30161Q1040

Tiempo real estimado Cboe BZX Otros sitios de cotización 20:57:30 23/05/2024			Varia. Cinco días.	Varia. 1 de enero.
20,42 ^USD	-2,74 %		-3,85 %	-14,91 %

20/05	Exelixis llega a un acuerdo con Cipla sobre el litigio de patentes de Cabometyx	MT
14/05	Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Exelixis Settles Cabometyx Patent Litigation with Cipla	20/05
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA	20/05
Exelixis Files Patent Complaint Against Cipla's Cancer Treatment	10/05
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May	07/05
Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours	30/04
Exelixis Guides For 2024 Revenue of $1.825-$1.925 Billion, vs CIQ Analyst Consensus of $1.91 Billion	30/04
Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $425.2M, vs. Street Est of $460.5M	30/04
Earnings Flash (EXEL) EXELIXIS Reports Q1 EPS $0.17, vs. Street Est of $0.29	30/04
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on January 8, 2024.	30/04
Exelixis: Q1 Earnings Snapshot	30/04
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update	30/04
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024	30/04
Exelixis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024	16/04
North American Morning Briefing : Big Banks Kick -2-	12/04
Jacqueline Wright Notifies Exelixis, Inc. of Her Decision Not to Stand for Re-Election to the Board of Directors	29/03
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March	27/02
BioInvent International AB Year-end report January 1, December 31, 2023	23/02
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing	22/02
BioInvent International AB Year-end report January 1 – December 31, 2023	22/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Exelixis, Inc.

Acciones

EXEL

US30161Q1040

Otros idiomas

Filtros